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Functional Measurements
To study renal excretion, mice were placed in metabolic cages for two days on control diet 
(C1000, Altromin, Lage, Germany) and tap water. Urinary creatinine and serum urea were 
measured using enzymatic colorimetric creatinine and urea kits (Lehmann, Berlin, Germany), 
Urinary albumin was measured using a fluorimetric albumin test kit (Progen, PR2005, 
Heidelberg, Germany) following the manufacturer´s instructions. Evaluation of albuminuria 
(expressed as the albumin to creatinine ratio) was performed as previously described 1.
Plasma concentrations of Na+, K+ and Ca2+ were measured by flame photometry (efux 5057, 
Eppendorf, Hamburg, Germany). Plasma and urinary magnesium and phosphorus 
concentration were determined by colorimetric methods (Lehmann, Berlin, Germany).
Urinary and plasma HPLC measurements
Amino acid concentrations in plasma and urine were determined on Biochrom 30+ amino 
acid analyzers (Laborservice Onken, Gründau, Germany), using cation exchange 
chromatography and post-column derivatization with ninhydrin. Prior to injection, samples 
were deproteinized with sulfosalicylic acid. External control was performed using the 
ERNDIM quality control scheme (www.erndimqa.nl) "Amino Acids".
Fixation and tissue processing for immunohistochemistry and immunoblotting 
Kidneys were shock-frozen for biochemical evaluation or perfused retrogradely using 4%
PFA in PBS and either postfixed o/n and subsequently transfered into 0.1% PFA in PBS for 
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paraffin embedding or processed for electronmicroscopy or transferred into 800 mOsm 
Sucrose in PBS overnight and subsequently frozen in OCT. Paraffin embedded sections 
were further processed for PAS-staining. To assess fluid phase and receptor mediated 
endocytosis HRP (Sigma, Schnelldorf, Germany) was given at a concentration of 120g/g 
BW and Alexa555 (Invitrogen, Karlsruhe, Germany) labeled ß-lactoglobulin (Sigma) at 4g/g 
BW i.v. into the retroorbital plexus under light isoflurane anesthesia. Kidneys were harvested 
5 min later and immediately perfused with 4% PFA in PBS and processed as described 
above. For electron microscopy tissue specimens were post-fixed in 1.5% glutaraldehyde 
and embedded in Epon 812 (Serva, Heidelberg, Deutschland) followed by contrasting 
ultrathin sections with osmium and uranylacetate. For isolation of membrane fractions
kidneys were homogenized in isolation buffer and processed as described 2. Total protein 
concentration was measured using the Pierce BCA Protein Assay reagent kit (Pierce,
Schwerte, Germany) and controlled by Coomassie staining.
SDS-PAGE and Immunoblotting
Proteins were solubilized and SDS gel electrophoresis was performed on 8-10% 
polyacrylamide gels. After electrophoretic transfer of the proteins to nitrocellulose 
membranes, equity in protein loading and blotting was verified by membrane staining using 
0.1% Ponceau red. Membranes were probed with primary antibodies and then exposed to 
HRP-conjugated secondary antibodies (Dianova, Hamburg, Germany). Immunoreactive 
bands were detected by chemiluminescence (Amersham Pharmacia, Glattbrugg, 
Switzerland). Densitometric evaluation was performed by BIO-PROFIL Bio-1D image 
software (Vilber Lourmat, Eberhardzell, Germany). 
Immunohistochemistry 
Cryosections were blocked with 5% skim milk/PBS, incubated with the respective primary 
antibody followed by the suitable cy-2 or cy-3-coupled secondary antibody (Dianova).
Double-antibody staining procedure was controlled by parallel incubation of consecutive 
sections, each probed only with one single antibody. Sections were analyzed using a 
multilaser confocal scanning microscope (SP5, Leica, Heerbrugg, Switzerland). 
Antibodies
The following antibodies were used: rabbit anti-raptor (24C12), rabbit anti-rictor (53A2),
rabbit anti-p70S6K (49D7), rabbit anti-phospho-p70S6K (108D2), rabbit anti-S6P (5G10),
rabbit anti-phospho-S6P (D57.2.2E), rabbit anti-4E-BP1 (53H11), rabbit anti-p-4E-BP1 
(T37/46, 236B4); all purchased from Cell Signaling Technologies and sheep anti-NDRG1, 
sheep anti-phospho-NDRG1 (kind gift of D. Alessi, University of Dundee, UK), guinea pig 
anti-megalin 3, goat anti-cubilin (Santa Cruz Biotechnology, Heidelberg, Germany, A-
20),rabbit anti-clathrin (Abcam, Cambridge UK, ab 21679), rabbit- anti B0AT1 4, rabbit- anti
y+LAT1 5, 4F2hc (CD98 M-20, Santa Cruz Biotechnology, Heidelberg, Germany), DOCK8
(ab121177 Abcam), BCL-xL (54H6 Cell Signaling Technologies) and Alexa647-coubled 
phalloidin (ThermoFischer Scientific, Zug, Switzerland).
Electron microscopic evaluation
Ultrathin sections were analyzed using a transmission electron microscope Philips CM12. 
Images were taken from transverse sectioned S1 segments near the urinary pole and 
ultrastructural parameters such as microvilli length, number of microvilli per inner diameter 
length, number of total endocytic vesicles per cell area, number of early endosomes and late 
endosomes per cell area and mitochondria per cell area were evaluated morphometrically 
using Fiji software (1.49k). To avoid evaluation of tangentially sectioned epithelia, parallel 
alignment of BBM microvilli was used as a criterion. Only patent tubules were examined.
Cell culture, viral transfection and treatment
Opossum kidney cells (OKC) were kindly provided by H. Murer, University of Zürich,
Switzerland. Cells were cultured at 37°C in 95% air/ 5% CO2 in high-glucose (450 mg/dl) 
DMEM supplemented with 5% fetal bovine serum, penicillin (100 U/ml), and streptomycin 
(100 g/ml). OKC were transduced with recombinant adenovirus expressing shRNA targeting 
human p70S6K (S6K1) and rictor driven by the U6 promoter (kindly provided by Z. Yang, 
Fribourg, Switzerland 6). Targeting sequences was in congruent with the respective opossum 
cDNA sequences. Viral titer was determined by QuickTiter™ Adenovirus Titer Immunoassay 
Kit (LuBio Science, Luzern, Switzerland). The control recombinant adenoviruses expressing 
shRNA targeting LacZ was from Invitrogen life Technologies, Zug, Switzerland. S6K1 
targeting sequence: GGACATGGCAGGAGTGTTTGA; Rictor targeting sequence: 
ACTTGTGAAGAATCGTATCTT. At a confluence of 70-90% OKC were transduced with the 
recombinant adenovirus at titers of 100 MOI and cultured in complete medium for 3–5 days.
Degree of knockdown was verified by TaqMan of S6K1 mRNA (Hs00177357_m1) compared 
to the housekeeping mRNA Tata-box binding protein (Mm00446973_m1) and the protein 
expression by western blot analysis of S6K1 and rictor. In comparison to MOCK 
transduction, OKC transduced with either S6K1 shRNA alone or S6K1 and rictor shRNA 
revealed a knockdown of S6K1 mRNA of -68 ± 12% and -67 ± 11%, *p < 0.05 respectively. 
S6K1 protein expression was reduced by -69 ± 15% and -63 ± 12%, respectively. Rictor 
protein expression was in comparison to MOCK transduction reduced by -66 ± 17% and by –
87 ± 20% for OKC treated either with rictor shRNA alone or S6K1 and rictor shRNA, 
respectively.
In the case of endocytosis assay, cells were serum-starved overnight. Confluent OKC were 
incubated either for 3 days with various mTOR kinase inhibitors or overnight with various 
concentrations of rapamycin. Additionally, p70S6K specific inhibitor PF-4708671 incubated 
for 16-18h was used. If not otherwise indicated the following concentrations were used; 100 
nM rapamycin, 250 nM torin, 100 nM PP242 and 3 M and 10 M PF-4708671 (Sigma 
Aldrich) in FCS-free medium. 10 M colchicine (Sigma Aldrich), a microtubule inhibitor, was 
always used overnight. Subsequently, the endocytosis assay was performed by incubating 
OKC with 0.1 mg/ml Alexa647-coupled albumin (Molecular Probes, Zug, Switzerland) for 30 
minutes, followed by extensive washing, fixing with 3%PFA in PBS and flow cytometry 
measurements. The downstream effects of various concentrations of rapamycin incubated 
overnight was tested by immunoprecipitation of 4E-BP1 followed by western blot analysis of 
p-4E-BP1. Afterwards membranes were stripped and revealed with anti-4E-BP1 antibody. 
The ratios of p-4E-BP1/4E-BP1 with increasing concentrations of rapamycin were: 0 nM: 100 
± 31%, 5 nM: 79 ± 17%, 10 nM: 75 ± 7%, 100 nM 62 ± 13% and 500 nM: 63 ± 21 %.
Measurement of lysosomal pH and enzyme activity
The pH of lysosomes was measured with LysoSensor Yellow/Blue DND-160 (Molecular 
Probes, Zug, Switzerland) according to the manufacturer’s protocol. In brief, OKC were 
collected by trypsin/EDTA and stained with LysoSensor at 1:200 concentrations in standard 
culture medium for 10 minutes followed by washing with PBS. Fluorescence of cell 
suspension in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 7.0) was measured by 
a microtiter plate at excitation 365 nm/emission 450 nm (for blue) and 485 nm/emission 550 
nm (for yellow). Standard curves were obtained in each sample using pH-fixed MES-buffer 
(pH 4.0 - 6.5) with 10 M nigericin (Sigma Aldrich, St. Gallen, Switzerland) and 10 M 
monensin (Sigma Aldrich). 
The activity of lysosomal enzymes was measured by incubating homogenate of virally 
transduced OK cells with the appropriate substrate. The reaction was allowed to proceed for 
30 minutes at 37°C and then stopped with 5 mL of 85 mM glycine-carbonate buffer (pH 
10.5). 200L of homogenate was incubated with 100L of 0.5 mM 4-methylumbelliferyl (MU)-
ȕ-galactoside in 100 mM citrate-SKRVSKDWH EXIIHU S+  ZLWK  0 1D&O ȕ-
Glucuronidase was measured by incubating 200L of homogenate with of 100L of 1 mM 4-
MU-ȕ-d-glucuronLGH LQ P0DFHWDWH EXIIHU S+ Į-Mannosidase was measured by 
incubating 50L of homogenate with 100 L of 4 mM 4-MU-Į- d-mannopyranoside in 100 
mM citrate-phosphate buffer (pH 4.0). The substrates were purchased from Sigma Aldrich, 
St. Gallen, Switzerland. The released 4-MU was measured against blank and standard 4-MU 
solutions. Fluorescence was determined with a Perkin Elmer 2030 Multilabel Reader Victor 
X3 at 450 nm after excitation at 360 nm.
D. melanogaster nephrocyte model system
D. melanogaster stocks were cultured on standard cornmeal molasses agar food and 
maintained at 25°C. RNAi-Based Nephrocyte Functional Screen Procedure: Virgins from 
MHC-ANF-RFP, HandGFP, and Dot-Gal4 transgenic lines (Gift from Zhe Han, University of 
Michigan, Ann Arbor, USA) were crossed to UAS-CG8487-RNAi (VDRC TID 42140/GD) 
males at 25°C; 2 days after crossing, flies were transferred to small collection cages with 
grape juice agar plates to collect the embryos for 24 hours at 25°C. Collected embryos were
aged for 48 hours at 29° C and then subjected to examination of the RFP accumulation in 
pericardial nephrocytes using a confocal microscope. The RFP mean fluorescence intensity 
of GFP positive areas was measured to quantify the uptake efficiency. 
Virgins of prospero-Gal4 (gift from Barry Denholm, University of Edinburgh, Edinburgh, UK)
were crossed to UAS-CG8487-RNAi males (VDRC TID 42140/GD) for a GCN-specific 
knockdown of Gartenzwerg. GCN preparations for TEM were fixed in 4% PFA and 1 % 
Glutaraldehyde and embedded in low melting Agarose. Tissue samples were then 
embedded in epoxy resin (Durcopan, Plano, Germany). Ultrathin sections of 40nm thickness 
were analyzed using a Zeiss TEM 906 (Zeiss, Oberkochen, Germany).
Sample preparation for MS/MS
Snap frozen kidney cortex were homogenized on ice and solubilized in 8M cold urea buffer 
containing 50mM ammonium bicarbonate and 1x Protease and phosphatase inhibitor 
cocktail (Pierce, ThermoFischer Scientific, Rockford, USA). Lysates were cleared with a 20 
min spin of 20.000 g in a benchtop centrifuge. Next, the supernatant was recovered and 
proteins were reduced, alkylated and digested at a 1:100 w/w trypsin/total protein ratio as 
previously described 7. Protein abundance was measured using a commercial BCA assay 
(Pierce). 5% of the digest was retained for proteomic analysis.  800 g of the remaining 
peptides was subjected to phosphopeptide enrichment using Fe-NTA immobilized metal 
affinity chromatography columns (Pierce) without further fractionation as previously 
described 7, 8. All samples were cleaned up using C18 resin in stage tips as previously 
described 9.
Nano-liquid chromatography and mass spectrometry
The cleaned peptides were separated using nLC on a house-packed 50cm C18 column in a 
column oven. The particle size was ௗȝm C18 beads (Dr Maisch GmbH, Ammerbuch-
Entringen, Germany). We analyzed the peptides using the following solvent gradient with 
ascending concentrations of buffer B as compared to buffer A.: t=0min; 4% [Buffer B], 05 
min, 6%; 125 min, 23%; 132 min, 54%; 138 min, 85% ; 143 min, 85%; 145 min 5%). Buffer B 
was 80% ACN, 0.1% FA and buffer A was 0.1% FA. The flow rate was constant with 250 
nl/min. The phosphopeptides were separated using nLC with the following gradient (0min, 
10% [Buffer B]; 5min, 10%; 125 min; 38%, 132 min 60%; 138, 95; 143, 95%; 148 min; 95% 
and 148 min 5%) Peptides were directly sprayed into a quadrupole-orbitrap based mass 
spectrometer QExactive Plus (Thermo) run in positive ion mode as previously described 10. 
The acquisition parameters were as follows: A MS1 precursor scan was followed by 10 MS2 
scans of the most intense ions (Top10 method). The resolution was 70000 for MS1 scans 
and 17500 for MS2 scans. AGC target was 3e6 for MS1 scans, and 5e5 for MS2 scans. 
Mass range was 300-1750 m/z for MS1 scans, and 200-2000 m/z for MS2 scans. Isolation 
window was 2.1 m/z, dynamic exclusion was enabled (20s). 
Bioinformatic analysis
Raw files were searched using the MaxQuant software package, v 1.5.1.0 11, including LFQ 
algorithm 12. The raw data were searched against a recent uniprot reference proteome 
database for mouse including common potential contaminants (Decoy mode: revert). The 
parameters were mainly default with a few modifications: Carbamidomethylation of cysteins 
as fixed modification, deisotoping enabled, mass accuracy for first search 20ppm, for second 
search 4.5 ppm. PSM, protein and site FDR was set to 0.01, minimal peptide length was 7, 
score for unmodified peptides was 0, and modified was 16. At least one peptide was 
necessary for protein identification. Variable modifications included N-terminal acetylation 
and methionine oxidation. In addition, phosphorylation (mass shift approximately +80) on 
STY residue was added as a variable modification for samples enriched for phosphorylated 
peptides. Match between runs (matching time 0.7min, matching window 20min) and label 
free quantification was enabled. At least 2 counts were necessary for a ratio. The MaxQuant 
output .txt files (PhosphoSTY.txt and proteingroups.txt) were then analyzed, visualized and 
normalized using the Perseus software, v. 1.5.1.0. For LFQ, only 5 missing values were 
tolerated, and for phosphorylation sites no missing value was tolerated. All other proteins or 
sites were filtered from the dataset. Two samples, for which identification count and/or 
MS/MS run was not sufficient (protein identification number less than -1SD from the mean) 
were removed entirely from the analysis. Missing values were imputed (SD downshift 1.8, 
width 0.3) after logarithmizing intensities and checking for normal distribution. Hierarchical 
clustering was performed based on the Euclidean distance. Vulcano plots were generated 
after a paired two-sample t-test. To determine significantly changed proteins, and to 
circumvent the multiple testing problem, a statistical approach similar to significance analysis 
of microarrays (SAM) 13 was utilized. This approach can also be applied to proteomics data. 
The threshold for significance was 0.3 after 250 randomizations (s0=1). Proteins and 
phosphorylation sites considered significant were exported and depicted in the respective 
tables. GO terms, keywords (uniprot) as well as PFAM domains and KEGG pathways were 
annotated using the Perseus annotation packages. Next, a fishers exact test was performed 
to assess whether there were special categories overrepresented in the changed protein and 
site populations as compared to the non-changed entities (for proteins, this test was 
performed separately for the significantly increased and the significantly decreased proteins).
The significantly changed GO terms were reanalyzed and condensed using Revigo 14 and
visualized in Cytoscape 15. The cumulative histogram was generated using the Prism 
(Graphpad) software. Phosphorylation motifs of the upregulated or downregulated 
phosphopeptide population were generated using the phosphologo software 16. Known 
phosphosites, known substrates and regulatory sites were added manually to the Table S4. 
Using a binary decision tree we separated the phosphorylation motifs in “basophilic”, 
“proline-directed”, “acidophilic” and “others”. 17
All MS raw files, including search results and metadata, are deposited at the 
ProteomeXchange repository 18. Project accession: PXD002422
(http://www.ebi.ac.uk/pride/archive/projects/PXD002422).
Supplemental Figure Legends
Supplementary Fig. 1. Triple labeling of either mTOR, RAPTOR, S6K1, S6P or NDRG1 
(red); megalin (green) and phalloidin to stain actin filaments (blue) on control mouse renal 
sections. (A) mTOR is localized to the subapical membrane region, (A’) merged image 
demonstrating proximal tubular expression. Insert of (A’) is depicted in (A’’) showing mTOR 
localized in vicinity to megalin. (B) RAPTOR localizes to vesicles of the subapical membrane 
region of S1 and S2 portions of the proximal tubule, (B’) merged image demonstrating 
proximal tubular expression. For more detailed analysis insert of (B’) is depicted in (B’’)
presenting a partial overlap between RAPTOR and megalin. (C) S6K1 is found in vesicular 
structures of the subapical membrane region and throughout the cytoplasm, (C’) merged
image demonstrating proximal tubular expression. Note, S3 segments marked by an asterisk 
are devoid of vesicular expression and show only intracellular staining. Insert of (C’) is 
depicted in (C’’) showing the vesicular structures positive for S6K1 and megalin in the S1 
segment. (D) Ribosomal S6 protein (S6P) is found in the apical membrane region of the 
proximal tubule; (D’) merged image is verifying proximal tubular expression. Insert of (D’) is 
depicted in (D’’) showing ribosomal S6P expression in close vicinity to megalin with 
occasional overlap. (E) NDRG1 is found to be expressed in the apical membrane region of 
the convoluted part of the proximal tubule; (E’) merged image is verifying proximal tubular 
expression. Asterisk marks the S3 segment of the proximal tubule which lacks a NDRG1 
signal. Insert of (E’) is depicted in (E’’) showing partial coexpression of NDRG1 and megalin. 
Magnification as indicated by scale bar.
Supplementary Fig. 2. (A) Urinary acidic and basic amino acid excretion of Rap'Tubule, 
Ric'Tubule and RapRic'Tubule. (B) Serum concentration of neutral, acidic and basic amino acids 
of Rap'Tubule, Ric'Tubule and RapRic'Tubule. *P-value vs. control <0.05; ** P-value vs. control 
<0.01.
Supplementary Fig.3. Immunohistochemical staining of MEGALIN (A) and CUBILIN (B) on 
Rap'Tubule, Ric'Tubule and RapRic'Tubule in comparison to their respective control. (C) Western 
blot analysis of MEGALIN from Rap'Tubule, Ric'Tubule and RapRic'Tubule. Densitometric analysis 
of MEGALIN western blots from Rap'Tubule, Ric'Tubule and RapRic'Tubule. No significant 
difference in expression intensity or subcellular distribution were observed.  
Supplementary Fig. 4. Histological alterations of Rap'Tubule and RapRic'Tubule 3 month after 
induction. (A) PAS-stained paraffin sections of Con, Rap'Tubule and RapRic'Tubule. Black 
stippled line indicates boundary between cortex and outer medulla and yellow stippled line 
boundary between outer stripe and inner stripe. (B) Expression of MEGALIN from Con, 
Rap'Tubule and RapRic'Tubule. (C) Expression of CUBILIN from Con, Rap'Tubule and 
RapRic'Tubule. (D) Expression of Na+/K+-ATPase (NKA) from Con, Rap'Tubule and 
RapRic'Tubule. Distal tubules are indicated by an asterisk. Missorting of NKA containing 
vesicles towards the apical membrane in Rap'Tubule and RapRic'Tubule and reduced 
basolateral expression in RapRic'Tubule is shown. Magnification as indicated by scale bar.
Supplementary Fig. 5. Pharmacological inhibition of mTORC1, mTORC1/2 or P70S6K1
and knock-down of mTORC2 and/or P70S6K1-induced signaling in proximal tubule 
cells. (A) Quantitative evaluation of flow cytometrical analysis of endocytosis assay 
performed in opossum kidney cells (OKC) treated for 3 days with 100 nM rapamycin, 100 nM 
PP242 and 250 nM torin or overnight with 10 M colchicine. Representative image of flow 
cytometrical analysis (right). (B) Quantitative evaluation of flow cytometrical analysis of 
endocytosis assay performed on OKC treated with increasing concentrations of rapamycin or 
colchicine overnight. Representative image of flow cytometrical analysis (right). (C) 
Quantitative evaluation of flow cytometrical analysis of endocytosis assay performed on OKC 
treated with 3M and 10 M PF-4708671 (PF) and 100nM rapamycin for 16-18 hours. 
Representative image of flow cytometrical analysis (right). (D) Quantitative evaluation of flow 
cytometrical analysis of endocytosis assay performed on viral transduced OKC with 
knockdown of S6K1, RICTOR or both proteins. Representative image of flow cytometrical 
analysis (right). (E) Lysosomal pH of virally transduced OKC with knockdown of S6K1, 
RICTOR or both proteins. (F) Quantitative assessment of clathrin-coated vesicles per Pm3 of 
virally transduced OKC with knockdown of S6K1, RICTOR or both proteins. (G) 
Representative images of merged z-scans in a 3D illustration are depicted. Scale bar = 40 
Pm. *P-value vs. control <0.05; ** P-value vs. control <0.01; #P-value vs. control <0.001.
Supplemental tables
Supplemental Table 1. Physiological parameters of Con, Rap'Tubule, Ric'Tubule and 
RapRic'Tubule. All values are rounded means given with min-max and n-number. *P-value vs. 
control <0.05; ** P-value vs. control <0.01.
Supplemental Table 2. Quantitative electron microscopy analysis. Microvilli length, number 
of microvilli per length cell surface, number of vesicles per cell area and mitochondrial area 
per cell area given in % of Rap'Tubule, Ric'Tubule and RapRic'Tubule in comparison to their 
respective controls. *P-value vs. control <0.05; **P-value vs. control <0.01; #P-value vs 
control <0.001.
Supplemental Table 3. Identified proteins with significant changes in expression level of 
Rap'Tubule in comparison to control. (A) Proteins which were significantly increased, (B) 
proteins which were significantly reduced. 
Supplemental Table 4. Identified changes of phosphorylation level of proteins of Rap'Tubule
in comparison to control. (A) Phosphorylation sites of proteins which were significantly 
increased, (B) phosphorylation sites of proteins which were significantly reduced. In addition 
known phosphosites, substrates and regulatory sites are indicated.
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microvilli lenght in 
m
number of 
microvilli per m 
lenght cell surface
Number of 
vesicles per cell 
area
Mitochondria in 
%
Con 1.71 ± 0.23 4.91 ± 0.41 1.01 ± 0.14 40.53 ± 5.13
Rap'Tubule 1.25 ± 0.04** 3.42 ± 0.49# 0.71 ± 0.04** 37.42 ± 2.35
Con 1.52 ± 0.19 5.05 ± 0.61 1.05 ± 0.12 41.45 ± 5.77
Ric'Tubulue 1.31 ± 0.17* 3.38 ± 0.65* 0.83 ± 0.15* 37.52 ± 3.57
Con 1.55 ± 0.16 4.81 ± 0.44 1.00 ± 0.12 39.58 ± 2.71
RapRic'Tubule 1.06 ± 0.05# 2.98 ± 0.17# 0.58 ± 0.06# 32.12 ± 3.47*
A. Proteins increased in Rap 'Tubule as compared to control
Gene
names Uniprot Protein names
log2 intensity 
(Rap/control) -log(P-value)
Obp1a Q9D3H2 MCG117626 3,02 2,50
Rplp1 P47955 60S acidic ribosomal protein P1 2,93 1,49
Ipo4 Q8VI75 Importin-4 2,65 1,58
Reg3g O09049 Regenerating islet-derived protein 3-gamma 2,64 1,47
Parpbp Q6IRT3 PCNA-interacting partner 2,62 0,67
Ppp2r4 P58389 Serine/threonine-protein phosphatase 2A activator 2,55 2,64
Retn Q99P87 Resistin 2,54 3,80
Ahsg P29699 Alpha-2-HS-glycoprotein 2,51 3,55
Gm14743 A2BHD2 Protein Gm14743 2,38 2,78
Reg1 P43137 Lithostathine-1 2,33 2,12
Guca2b O09051 Guanylate cyclase activator 2B 2,26 4,00
Ambp Q07456 Protein AMBP 2,24 3,56
Napsa O09043 Napsin-A 2,23 1,75
Cops7a Q9CZ04 COP9 signalosome complex subunit 7a 2,20 1,93
Scgb1a1 Q06318 Uteroglobin 2,16 1,42
Apoa4 P06728 Apolipoprotein A-IV 2,11 3,39
Ttr P07309 Transthyretin 2,10 2,25
Agt P11859 Angiotensinogen 2,04 3,98
Serpinf1 P97298 Pigment epithelium-derived factor 2,03 3,12
Gm2a Q60648 Ganglioside GM2 activator 2,00 4,89
Lyz2 P08905 Lysozyme C-2 1,99 4,12
Rbp4 Q00724 Retinol-binding protein 4 1,93 2,00
S100a6 P14069 Protein S100-A6 1,90 1,24
Apoc3 P33622 Apolipoprotein C-III 1,89 2,41
Cst3 P21460 Cystatin-C 1,87 4,07
Rnase4 Q8C7E4 Ribonuclease 4 1,87 3,36
Cpq Q9WVJ3 Carboxypeptidase Q 1,86 1,37
Gc P21614 Vitamin D-binding protein 1,82 3,40
Cox6b1 P56391 Cytochrome c oxidase subunit 6B1 1,75 1,17
Ctbs Q8R242 Di-N-acetylchitobiase 1,74 2,73
Chi3l3 O35744 Chitinase-3-like protein 3 1,66 3,28
Slc37a4 Q9D1F9 Protein Slc37a4 1,63 0,83
Chchd2 Q9D1L0 Coiled-coil-helix-coiled-coil-helix domain-containing protein 2, mitochondrial 1,62 1,68
Nup155 Q99P88 Nuclear pore complex protein Nup155 1,59 1,39
Dsg4 Q7TMD7 Desmoglein-4 1,55 0,70
Igfbp2 D3YU40 Insulin-like growth factor-binding protein 2 1,55 1,50
C4b P01029 Complement C4-B 1,54 3,38
Arl2 Q9D0J4 ADP-ribosylation factor-like protein 2 1,54 2,18
Tgfb1i1 E9PYQ1 Transforming growth factor beta-1-induced transcript 1 protein 1,54 1,76
Cd5l Q9QWK4 CD5 antigen-like 1,52 4,55
Cfb P04186 Complement factor B 1,52 1,68
Kng2 Q6S9I0 Kng2 protein 1,49 1,82
Eva1a D3Z511 Protein eva-1 homolog A 1,48 2,18
N/A P01837 Ig kappa chain C region 1,47 1,99
S100a10 P08207 Protein S100-A10 1,47 1,47
Snrpb P27048 Small nuclear ribonucleoprotein-associated protein B 1,46 1,18
Abhd11 Q8K4F5 Alpha/beta hydrolase domain-containing protein 11 1,44 0,84
Sept6 Q9R1T4 Septin-6 1,44 1,70
Prelp Q9JK53 Prolargin 1,43 1,47
Mtx2 O88441 Metaxin-2 1,42 0,90
Ctbp1 O88712 C-terminal-binding protein 1 1,40 0,71
Retnlg Q8K426 Myeloid cysteine-rich protein 1,39 1,59
Lsm14a Q8K2F8 Protein LSM14 homolog A 1,39 1,32
Cyp4a12a Q91WL5 Cytochrome P450 4A12A 1,37 0,76
Nek7 Q9ES74 Serine/threonine-protein kinase Nek7 1,37 1,59
Uqcrq Q9CQ69 Cytochrome b-c1 complex subunit 8 1,36 0,78
Amy1 P00687 Alpha-amylase 1 1,36 0,83
Hao2 Q9NYQ2 Hydroxyacid oxidase 2 1,34 2,07
Glyctk Q8QZY2 Glycerate kinase 1,33 1,77
Snrnp40 Q6PE01 U5 small nuclear ribonucleoprotein 40 kDa protein 1,32 1,09
Hpx Q91X72 Hemopexin 1,29 2,53
Tstd1 E9PY03 Protein Tstd1 1,26 1,09
Slc10a2 P70172 Ileal sodium/bile acid cotransporter 1,24 1,97
B2m P01887 Beta-2-microglobulin 1,23 2,45
Erp29 P57759 Endoplasmic reticulum resident protein 29 1,22 1,45
Apoa1 Q00623 Apolipoprotein A-I 1,21 1,92
Spink3 P09036 Serine protease inhibitor Kazal-type 3 1,19 2,68
Snrpc Q62241 U1 small nuclear ribonucleoprotein C 1,19 0,97
Myg1 F8WGG3 UPF0160 protein MYG1, mitochondrial 1,16 1,93
Hamp Q9EQ21 Hepcidin 1,16 1,78
Nt5e Q61503 5-nucleotidase 1,13 1,63
Them7 Q9DCP4 Novel Thioesterase superfamily domain and Saposin A-type domain contain 1,13 3,68
Eefsec Q9JHW4 Selenocysteine-specific elongation factor 1,12 1,57
Man2b1 O09159 Lysosomal alpha-mannosidase 1,12 1,55
Fnbp1l E9PUK3 Formin-binding protein 1-like 1,11 1,34
N/A P01843 Ig lambda-1 chain C region 1,11 1,49
Tpm1 B7ZNL3 ropomyosin alpha-1 chain 1,09 1,62
Enpep P16406 Glutamyl aminopeptidase 1,04 2,18
Ace2 Q8R0I0 Angiotensin-converting enzyme 2 1,04 3,46
Blvrb Q923D2 Flavin reductase (NADPH) 1,02 2,18
Ren1 P06281 Renin-1 1,01 2,01
Fdx1l Q9CPW2 Adrenodoxin-like protein, mitochondrial 0,98 1,53
Cpsf6 Q6NVF9 Cleavage and polyadenylation specificity factor subunit 6 0,97 1,63
B. Proteins decreased in Rap 'Tubule as compared to control
Gene
names Uniprot Protein names
log2 intensity 
(Rap/control) -log(P-value)
Thsd4 Q3UTY6 Thrombospondin type-1 domain-containing protein 4 -2,79 0,98
4933436I01RQ9D3T1 Protein 4933436I01Rik -2,73 1,18
Dock8 Q8C147 Dedicator of cytokinesis protein 8 -2,70 0,82
Dnah10 F7ABZ6 Protein Dnah10 -2,50 1,89
Slc26a1 P58735 Sulfate anion transporter 1 -2,22 1,30
Slc7a7 Q9Z1K8 Y+L amino acid transporter 1 -2,08 1,55
Bloc1s5 Q8R015 Biogenesis of lysosome-related organelles complex 1 subunit 5 -1,89 0,64
Rtn3 Q9ES97 Reticulon-3 -1,89 1,17
Ppp6r1 Q7TSI3 Serine/threonine-protein phosphatase 6 regulatory subunit 1 -1,73 2,61
Dnajc12 Q9R022 DnaJ homolog subfamily C member 12 -1,57 3,45
Bcl2l1 A2AHX9 Bcl-2-like protein 1 -1,55 1,03
Fbxo22 D6REV6 F-box only protein 22 -1,55 2,20
Slc6a19 D6RJ80 Sodium-dependent neutral amino acid transporter B(0)AT1 -1,54 1,22
Slc5a12 Q49B93 Sodium-coupled monocarboxylate transporter 2 -1,51 4,94
Rab10 P61027 Ras-related protein Rab-10 -1,48 1,25
Uros Q3TPL3 Uroporphyrinogen-III synthase -1,44 0,82
Cbx1 P83917 Chromobox protein homolog 1 -1,39 0,95
Sdc4 O35988 Syndecan-4 -1,39 1,39
Cyp51a1 Q8K0C4 Lanosterol 14-alpha demethylase -1,38 1,20
Ankrd44 J3QK13 Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B -1,35 0,94
Snx8 Q8CFD4 Sorting nexin-8 -1,24 1,05
Phgdh Q61753 D-3-phosphoglycerate dehydrogenase -1,21 3,57
Mrpl13 Q9D1P0 39S ribosomal protein L13, mitochondrial -1,20 1,26
Larp1 Z4YJT3 La-related protein 1 -1,13 1,68
Nccrp1 G3X9C2 F-box only protein 50 -1,12 1,06
G6pc P35576 Glucose-6-phosphatase -1,11 1,04
Slc16a1 P53986 Monocarboxylate transporter 1 -1,10 3,58
Hspa14 Q99M31 Heat shock 70 kDa protein 14 -1,09 1,22
Glul P15105 Glutamine synthetase -1,08 4,29
Chd4 E9QAS4 Chromodomain-helicase-DNA-binding protein 4 -1,02 1,47
Rhot1 Q8BG51 Mitochondrial Rho GTPase 1 -1,00 1,45
Slc43a2 Q8CGA3 Large neutral amino acids transporter small subunit 4 -1,00 2,96
Rpl6 P47911 60S ribosomal protein L6 -0,99 2,74
Rpl7 P14148 60S ribosomal protein L7 -0,93 1,79
Rpl26 P61255 60S ribosomal protein L26 -0,91 3,96
Ca14 Q9WVT6 Carbonic anhydrase 14 -0,91 2,50
Aacs Q9D2R0 Acetoacetyl-CoA synthetase -0,89 4,05
Slc3a2 P10852 4F2 cell-surface antigen heavy chain -0,88 4,26
Rpl19 A2A547 60S ribosomal protein L19 -0,88 2,53
Slc22a8 O88909 Solute carrier family 22 member 8 -0,82 3,07
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